Athira Pharma (NASDAQ:ATHA) Trading Up 1.3% – Here’s Why

Athira Pharma, Inc. (NASDAQ:ATHA)’s stock price traded up 1.3% during trading on Friday . The company traded as high as $0.32 and last traded at $0.31. 111,112 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,480,716 shares. The stock had previously closed at $0.30.

Athira Pharma Price Performance

The stock’s 50 day moving average price is $0.42 and its two-hundred day moving average price is $0.51. The firm has a market capitalization of $11.91 million, a price-to-earnings ratio of -0.11 and a beta of 3.00.

Athira Pharma (NASDAQ:ATHA) last released its earnings results on Thursday, February 27th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06. As a group, equities research analysts anticipate that Athira Pharma, Inc. will post -2.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Athira Pharma

An institutional investor recently bought a new position in Athira Pharma stock. BML Capital Management LLC purchased a new position in Athira Pharma, Inc. (NASDAQ:ATHA) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 2,775,885 shares of the company’s stock, valued at approximately $1,629,000. Athira Pharma accounts for 1.0% of BML Capital Management LLC’s holdings, making the stock its 15th largest position. BML Capital Management LLC owned approximately 7.18% of Athira Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.